Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
MyoKardia participates in a conference call with Cantor Fitzgerald » 16:41
06/01/20
06/01
16:41
06/01/20
16:41
MYOK

MyoKardia

$103.03 /

+0.61 (+0.60%)

Conference call with…

Conference call with management will be held on June 3 at 1:30 pm hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
MYOK MyoKardia
$103.03 /

+0.61 (+0.60%)

MYOK MyoKardia
$103.03 /

+0.61 (+0.60%)

05/20/20 Cantor Fitzgerald
MyoKardia price target raised to $188 from $95 at Cantor Fitzgerald
05/14/20 BMO Capital
MyoKardia price target raised to $148 from $90 at BMO Capital
05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
MYOK MyoKardia
$103.03 /

+0.61 (+0.60%)

MYOK MyoKardia
$103.03 /

+0.61 (+0.60%)

Over a week ago
Recommendations
MyoKardia price target raised to $188 from $95 at Cantor Fitzgerald » 07:17
05/20/20
05/20
07:17
05/20/20
07:17
MYOK

MyoKardia

$106.17 /

-3.9 (-3.54%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Alethia Young raised the firm's price target on MyoKardia to $188 from $95 and keeps an Overweight rating on the shares following last week's positive pivotal EXPLORER readout last week and updating her model to reflect success in the obstructive HCM population, with estimated peak sales of ~$3B. Young says the data were more robust than she expected and left little room for doubt on either efficacy or safety for mavacamten. She would remain bullish into filing and approval over the next 12 months.

ShowHide Related Items >><<
MYOK MyoKardia
$106.17 /

-3.9 (-3.54%)

MYOK MyoKardia
$106.17 /

-3.9 (-3.54%)

05/14/20 BMO Capital
MyoKardia price target raised to $148 from $90 at BMO Capital
05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
MYOK MyoKardia
$106.17 /

-3.9 (-3.54%)

MYOK MyoKardia
$106.17 /

-3.9 (-3.54%)

Recommendations
MyoKardia price target raised to $148 from $90 at BMO Capital » 08:18
05/14/20
05/14
08:18
05/14/20
08:18
MYOK

MyoKardia

$108.34 /

-3.95 (-3.52%)

BMO Capital analyst…

BMO Capital analyst George Farmer raised the firm's price target on MyoKardia to $148 from $90 and keeps an Outperform rating on the shares. The company's recent Phase 3 EXPLORER trial data evaluating mavacamtenfor treatment of obstructive hypertrophic cardiomyopaty was "highly meaningful" and supportive of a "robust treatment effect", while safety factors appear to be a "non-issue", the analyst tells investors in a research note. Farmer contends that regulatory approvals for mavacamtenfor should be "relatively straightforward".

ShowHide Related Items >><<
MYOK MyoKardia
$108.34 /

-3.95 (-3.52%)

MYOK MyoKardia
$108.34 /

-3.95 (-3.52%)

05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 H.C. Wainwright
Cytokinetics price target raised to $35 from $30 at H.C. Wainwright
MYOK MyoKardia
$108.34 /

-3.95 (-3.52%)

  • 13
    May
MYOK MyoKardia
$108.34 /

-3.95 (-3.52%)

Syndicate
MyoKardia 5.25M share Spot Secondary priced at $105 » 06:04
05/13/20
05/13
06:04
05/13/20
06:04
MYOK

MyoKardia

$112.29 /

+15.34 (+15.82%)

BofA, JPMorgan and Credit…

BofA, JPMorgan and Credit Suisse acted as joint book running managers for the offering.

ShowHide Related Items >><<
MYOK MyoKardia
$112.29 /

+15.34 (+15.82%)

MYOK MyoKardia
$112.29 /

+15.34 (+15.82%)

05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 H.C. Wainwright
Cytokinetics price target raised to $35 from $30 at H.C. Wainwright
MYOK MyoKardia
$112.29 /

+15.34 (+15.82%)

  • 13
    May
MYOK MyoKardia
$112.29 /

+15.34 (+15.82%)

Syndicate
MyoKardia 5.25M share spot secondary prices at $105/shr, Bloomberg says  20:12
05/12/20
05/12
20:12
05/12/20
20:12
MYOK

MyoKardia

$112.29 /

+15.34 (+15.82%)

 
ShowHide Related Items >><<
MYOK MyoKardia
$112.29 /

+15.34 (+15.82%)

MYOK MyoKardia
$112.29 /

+15.34 (+15.82%)

05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 H.C. Wainwright
Cytokinetics price target raised to $35 from $30 at H.C. Wainwright
MYOK MyoKardia
$112.29 /

+15.34 (+15.82%)

  • 13
    May
MYOK MyoKardia
$112.29 /

+15.34 (+15.82%)

Recommendations
MyoKardia takeout value in $160 to $190 per share range, says Citi » 06:22
05/12/20
05/12
06:22
05/12/20
06:22
MYOK

MyoKardia

$96.95 /

+35.88 (+58.75%)

Citi analyst Mohit Bansal…

Citi analyst Mohit Bansal raised the firm's price target on MyoKardia to $125 from $87 and keeps a Buy rating on the shares. The company's "home-run" EXPLORER trial data is just the beginning as its "Divide and Conquer" approach for cardiovascular indications could provide more such outcomes, Bansal tells investors in a research note. The analyst sees MyoKardia's takeout value in the $160-$190 per share range. The stock closed Monday up $35.81 to $96.90.

ShowHide Related Items >><<
MYOK MyoKardia
$96.95 /

+35.88 (+58.75%)

MYOK MyoKardia
$96.95 /

+35.88 (+58.75%)

05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 H.C. Wainwright
Cytokinetics price target raised to $35 from $30 at H.C. Wainwright
05/11/20 Piper Sandler
Piper boosts Cytokinetics target to $28 on positive MyoKardia read-through
MYOK MyoKardia
$96.95 /

+35.88 (+58.75%)

  • 13
    May
MYOK MyoKardia
$96.95 /

+35.88 (+58.75%)

On The Fly
Fly Intel: Wall Street's top stories for Monday » 17:23
05/11/20
05/11
17:23
05/11/20
17:23
TSLA

Tesla

$810.81 /

-8.2 (-1.00%)

, AMC

AMC Entertainment

$5.32 /

+1.225 (+29.91%)

, AMZN

Amazon.com

$2,408.00 /

+29.28 (+1.23%)

, QDEL

Quidel

$209.14 /

+50.59 (+31.91%)

, UAA

Under Armour

$9.00 /

-0.94 (-9.46%)

, UA

Under Armour

$8.01 /

-0.9 (-10.10%)

, MYOK

MyoKardia

$96.95 /

+35.88 (+58.75%)

, CAH

Cardinal Health

$53.23 /

+3.33 (+6.67%)

, AN

AutoNation

$39.41 /

+1.13 (+2.95%)

, SSRM

SSR Mining

$17.15 /

-0.97 (-5.35%)

, ALIAF

Alacer Gold

$0.00 /

+ (+0.00%)

, MOS

Mosaic

$11.22 /

-0.69 (-5.79%)

The S&P started the week…

Open Full Text

ShowHide Related Items >><<
UAA Under Armour
$9.00 /

-0.94 (-9.46%)

UA Under Armour
$8.01 /

-0.9 (-10.10%)

TSLA Tesla
$810.81 /

-8.2 (-1.00%)

SSRM SSR Mining
$17.15 /

-0.97 (-5.35%)

QDEL Quidel
$209.14 /

+50.59 (+31.91%)

MYOK MyoKardia
$96.95 /

+35.88 (+58.75%)

MOS Mosaic
$11.22 /

-0.69 (-5.79%)

CAH Cardinal Health
$53.23 /

+3.33 (+6.67%)

AN AutoNation
$39.41 /

+1.13 (+2.95%)

AMZN Amazon.com
$2,408.00 /

+29.28 (+1.23%)

AMC AMC Entertainment
$5.32 /

+1.225 (+29.91%)

TSLA Tesla
$810.81 /

-8.2 (-1.00%)

05/12/20 Wedbush
'Standoff at Fremont' begins as Tesla's Musk restarts engines, says Wedbush
05/11/20 Deutsche Bank
Tesla reiterated order backlog continues to grow, says Deutsche Bank
05/11/20 Wedbush
Moving away from Fremont could add risk to Tesla manufacturing, says Wedbush
05/07/20 Roth Capital
Tesla's reported suspension in Shanghai adds downside risk, says Roth Capital
AMC AMC Entertainment
$5.32 /

+1.225 (+29.91%)

05/11/20 B. Riley FBR
Amazon buyout may not appeal to AMC shareholders, says B. Riley FBR
04/30/20 Imperial Capital
AMC Entertainment price target raised to $3 from $2 at Imperial Capital
04/23/20 Macquarie
AMC Entertainment downgraded to Neutral from Outperform at Macquarie
04/22/20 JPMorgan
JPMorgan downgrades EPR after only15% of April rents get collected
AMZN Amazon.com
$2,408.00 /

+29.28 (+1.23%)

05/07/20 Piper Sandler
Fastly price target raised to $31 from $27 at Piper Sandler
05/06/20 China Renaissance
Amazon.com price target raised to $2,162 from $1,850 at China Renaissance
05/05/20 Stifel
Stifel downgrades Wayfair to Sell on return of Amazon competition
QDEL Quidel
$209.14 /

+50.59 (+31.91%)

05/12/20 JPMorgan
JPMorgan downgrades Quidel to Underweight on COVID opportunity skepticism
05/12/20 JPMorgan
Quidel downgraded to Underweight from Neutral at JPMorgan
05/07/20 Craig-Hallum
Quidel price target raised to $170 from $125 at Craig-Hallum
03/26/20 Barclays
Quidel downgraded to Equal Weight from Overweight at Barclays
UAA Under Armour
$9.00 /

-0.94 (-9.46%)

05/12/20 Raymond James
Under Armour price target lowered to $12 from $25 at Raymond James
05/12/20 Susquehanna
Under Armour price target lowered to $4 from $6 at Susquehanna
05/12/20 Barclays
Under Armour price target lowered to $9 from $10 at Barclays
05/08/20 Citi
Under Armour price target lowered to $15 from $17 at Citi
UA Under Armour
$8.01 /

-0.9 (-10.10%)

04/28/20 BTIG
Under Armour initiated with a Sell at BTIG
04/20/20
Fly Intel: Top five analyst upgrades
MYOK MyoKardia
$96.95 /

+35.88 (+58.75%)

05/12/20 Citi
MyoKardia takeout value in $160 to $190 per share range, says Citi
05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 H.C. Wainwright
Cytokinetics price target raised to $35 from $30 at H.C. Wainwright
CAH Cardinal Health
$53.23 /

+3.33 (+6.67%)

04/22/20 Credit Suisse
Cardinal Health assumed with a Neutral at Credit Suisse
03/20/20 BofA
Cardinal Health upgraded to Buy from Underperform at BofA
02/12/20 Morgan Stanley
Cardinal Health upgraded to Equal Weight from Underweight at Morgan Stanley
02/07/20 Baird
Cardinal Health upgraded to Outperform at Baird
AN AutoNation
$39.41 /

+1.13 (+2.95%)

05/12/20 SunTrust
AutoNation price target raised to $42 from $28 at SunTrust
04/27/20
Fly Intel: Top five analyst upgrades
04/27/20 Northcoast
AutoNation upgraded to Buy on potential dealer outperformance at Northcoast
04/27/20 Northcoast
AutoNation upgraded to Buy from Neutral at Northcoast
SSRM SSR Mining
$17.15 /

-0.97 (-5.35%)

02/24/20 Canaccord
SSR Mining downgraded to Hold from Buy at Canaccord
02/21/20 Scotiabank
SSR Mining downgraded to Sector Perform from Outperform at Scotiabank
11/13/19 B. Riley FBR
B. Riley FBR upgrades SSR Mining to Buy, boosts target to $23
11/13/19 B. Riley FBR
SSR Mining upgraded to Buy from Neutral at B. Riley FBR
ALIAF Alacer Gold
$0.00 /

+ (+0.00%)

05/05/20 RBC Capital
Alacer Gold price target raised to C$8 from C$7 at RBC Capital
05/01/20 CIBC
Alacer Gold price target raised to C$9 from C$8 at CIBC
04/01/20 BMO Capital
Alacer Gold upgraded to Outperform from Market Perform at BMO Capital
02/11/20 Stifel
Alacer Gold upgraded to Buy from Hold at Stifel
MOS Mosaic
$11.22 /

-0.69 (-5.79%)

05/11/20 BofA
Nutrien, Mosaic, Corteva, CF Industries cut to Underperform at BofA
05/11/20 BofA
Mosaic downgraded to Underperform from Buy at BofA
05/06/20 Scotiabank
Scotiabank sees 50% upside in Mosaic shares as markets stabilize
04/28/20 Cleveland Research
Cleveland Research lowers Mosaic estimates on long-term pricing concerns
UAA Under Armour
$9.00 /

-0.94 (-9.46%)

UA Under Armour
$8.01 /

-0.9 (-10.10%)

TSLA Tesla
$810.81 /

-8.2 (-1.00%)

SSRM SSR Mining
$17.15 /

-0.97 (-5.35%)

QDEL Quidel
$209.14 /

+50.59 (+31.91%)

MYOK MyoKardia
$96.95 /

+35.88 (+58.75%)

MOS Mosaic
$11.22 /

-0.69 (-5.79%)

CAH Cardinal Health
$53.23 /

+3.33 (+6.67%)

AN AutoNation
$39.41 /

+1.13 (+2.95%)

AMZN Amazon.com
$2,408.00 /

+29.28 (+1.23%)

AMC AMC Entertainment
$5.32 /

+1.225 (+29.91%)

  • 13
    May
UAA Under Armour
$9.00 /

-0.94 (-9.46%)

TSLA Tesla
$810.81 /

-8.2 (-1.00%)

CAH Cardinal Health
$53.23 /

+3.33 (+6.67%)

AN AutoNation
$39.41 /

+1.13 (+2.95%)

AMZN Amazon.com
$2,408.00 /

+29.28 (+1.23%)

AMC AMC Entertainment
$5.32 /

+1.225 (+29.91%)

UAA Under Armour
$9.00 /

-0.94 (-9.46%)

UA Under Armour
$8.01 /

-0.9 (-10.10%)

TSLA Tesla
$810.81 /

-8.2 (-1.00%)

MOS Mosaic
$11.22 /

-0.69 (-5.79%)

CAH Cardinal Health
$53.23 /

+3.33 (+6.67%)

AMZN Amazon.com
$2,408.00 /

+29.28 (+1.23%)

AMC AMC Entertainment
$5.32 /

+1.225 (+29.91%)

UAA Under Armour
$9.00 /

-0.94 (-9.46%)

UA Under Armour
$8.01 /

-0.9 (-10.10%)

TSLA Tesla
$810.81 /

-8.2 (-1.00%)

SSRM SSR Mining
$17.15 /

-0.97 (-5.35%)

MOS Mosaic
$11.22 /

-0.69 (-5.79%)

CAH Cardinal Health
$53.23 /

+3.33 (+6.67%)

AN AutoNation
$39.41 /

+1.13 (+2.95%)

AMZN Amazon.com
$2,408.00 /

+29.28 (+1.23%)

AMC AMC Entertainment
$5.32 /

+1.225 (+29.91%)

TSLA Tesla
$810.81 /

-8.2 (-1.00%)

AMZN Amazon.com
$2,408.00 /

+29.28 (+1.23%)

Syndicate
MyoKardia files to sell $450M in common stock » 16:03
05/11/20
05/11
16:03
05/11/20
16:03
MYOK

MyoKardia

$94.66 /

+33.59 (+55.00%)

BofA Securities, J.P.…

BofA Securities, J.P. Morgan and Credit Suisse are acting as joint bookrunning managers for the proposed offering. Cantor and Wells Fargo Securities are also acting as bookrunning managers in the offering. BMO Capital Markets and Wedbush PacGrow are acting as co-lead managers.

ShowHide Related Items >><<
MYOK MyoKardia
$94.66 /

+33.59 (+55.00%)

05/11/20 Cowen
MyoKardia price target raised to $145 from $104 at Cowen
05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 H.C. Wainwright
Cytokinetics price target raised to $35 from $30 at H.C. Wainwright
05/11/20 Piper Sandler
Piper boosts Cytokinetics target to $28 on positive MyoKardia read-through
Recommendations
MyoKardia price target raised to $145 from $104 at Cowen » 14:41
05/11/20
05/11
14:41
05/11/20
14:41
MYOK

MyoKardia

$99.27 /

+38.2 (+62.55%)

Cowen analyst Ritu Baral…

Cowen analyst Ritu Baral raised the firm's price target on MyoKardia to $145 from $104 and keeps an Outperform rating on the shares after the company announced top-line results from the EXPLORER-HCM study of mavacamten in obstructive hypertrophic cardiomyopathy.

ShowHide Related Items >><<
MYOK MyoKardia
$99.27 /

+38.2 (+62.55%)

05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/11/20 H.C. Wainwright
Cytokinetics price target raised to $35 from $30 at H.C. Wainwright
05/11/20 Piper Sandler
Piper boosts Cytokinetics target to $28 on positive MyoKardia read-through
05/11/20 Credit Suisse
MyoKardia price target raised to $136 from $82 at Credit Suisse
Recommendations
MyoKardia price target raised to $127 from $90 at Wedbush » 13:32
05/11/20
05/11
13:32
05/11/20
13:32
MYOK

MyoKardia

$99.97 /

+38.9 (+63.70%)

, NVS

Novartis

$86.02 /

+1.08 (+1.27%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$241.11 /

+6.25 (+2.66%)

Wedbush analyst David…

Wedbush analyst David Nierengarten raised the firm's price target on MyoKardia (MYOK) to $127 from $90 and keeps an Outperform rating on the shares following what he called "impressive" topline data from a Phase 3 trial of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy, or oHCM. The EXPLORER trial hit all of its primary and secondary endpoints with high statistical significance and safety was better than expected, Nierengarten said. He "fully expects" approval in Q4 of 2021, sees mavacamten climbing to worldwide sales across indications of greater than $4B by 2027, and views MyoKardia as an attractive M&A candidate for potential buyers that could include Novartis (NVS), Bayer (BAYRY), Amgen (AMGN) and others, Nierengarten tells investors.

ShowHide Related Items >><<
MYOK MyoKardia
$99.97 /

+38.9 (+63.70%)

05/11/20 H.C. Wainwright
Cytokinetics price target raised to $35 from $30 at H.C. Wainwright
05/11/20 Piper Sandler
Piper boosts Cytokinetics target to $28 on positive MyoKardia read-through
05/11/20 Credit Suisse
MyoKardia price target raised to $136 from $82 at Credit Suisse
05/11/20 JPMorgan
MyoKardia could head to $100-$115 per share on 'homerun' data, says JPMorgan
NVS Novartis
$86.02 /

+1.08 (+1.27%)

05/11/20 UBS
Novartis price target lowered to CHF 88 from CHF 90 at UBS
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
04/29/20 JPMorgan
Novartis price target lowered to CHF 84 from CHF 91 at JPMorgan
04/29/20 Barclays
Novartis price target raised to CHF 75 from CHF 70 at Barclays
BAYRY Bayer
$0.00 /

+ (+0.00%)

04/22/20 Morgan Stanley
Bayer price target lowered to EUR 83 from EUR 86 at Morgan Stanley
03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
03/04/20 Deutsche Bank
Bayer upgraded to Buy from Hold at Deutsche Bank
AMGN Amgen
$241.11 /

+6.25 (+2.66%)

05/04/20 Cantor Fitzgerald
Amgen price target raised to $263 from $255 at Cantor Fitzgerald
05/01/20 BMO Capital
Amgen price target raised to $291 from $274 at BMO Capital
05/01/20 Wells Fargo
Amgen price target raised to $237 from $220 at Wells Fargo
04/30/20 Piper Sandler
Amgen price target raised to $255 from $235 at Piper Sandler

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.